Effect and Mechanism of Cognitive Behavioral Therapy combined Chemoradiotherapy on Radiosensitivity of Nasopharyngeal Carcinoma: a Randomized Controlled Trial.

Conditions

nasopharyngeal carcinoma

Liu F, Fu SN, Yan OY, Chen YZ, Jiang C, Wu X, Han YQ, Wang H.

2021-11-01

10.1016/j.ijrobp.2021.07.266

A randomized controlled trial of cognitive behavior therapy for reducing anxiety and depressive symptoms in patients with locoregional advanced nasopharyngeal carcinoma.

Feng Liu, Shengnan Fu, Yanzhu Chen, Ouying Yan, Xiangwei Wu et al. (12 authors)

Journal of Clinical Oncology2021-05-20

10.1200/jco.2021.39.15_suppl.12121

Effects of Cognitive Behavioral Therapy for Depression and Anxiety, Response Rates and Adverse Events in Patients with Locoregional Advanced Nasopharyngeal Carcinoma

Feng Liu, Shengnan Fu, Yanzhu Chen, Ouying Yan, Fei Tong et al. (17 authors)

Integrative Cancer Therapies2021-01-0110 citations

10.1177/15347354211006179

Interventions

group CBT :Cognitive behavioral therapy combined with radiotherapy and chemotherapy

Treatment as usual (TAU) group :Routine health education combined with radiotherapy and chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Eligible patients will be 18 to 70 years ages with nasopharyngeal carcinoma confirmed by pathology, excluding patients with AJCC stage I(8th Union for International Cancer Control, UICC) and histologically proven WHO types II-III. 2. All participants have Karnofsky scores of at least 70, and adequate liver, and renal functions. 3. Patients' (HADS) score of Hospital anxiety and Depression scale is less than 11 points. 4. Patients can participate in cognitive behavioral therapy and can required to provide written informed consent.

Exclusion criteria

Exclusion criteria: Patients with history of previous radiotherapy, secondary malignancy, pregnancy or lactation, severe psychological, cognitive, mental disorders, such as suicidal tendencies, etc. are excluded from the study.

Design outcomes

Primary

Measure	Time frame
overall survival (OS);Hospital Anxiety and Depression Scale (HADS);	—

Secondary

Measure	Time frame
local recurrence-free survival (LRFS);RRFS;loco-regional recurrence-free survival (LRRFS);distant metastasis-free survival (DMFS);disease-free survival (DFS);acute and late toxic reactions;	—

Countries

China

Contacts

Public ContactLiu Feng

Department of Radiation Oncology, Hunan Cancer Hospital

liufeng820111@163.com+86 18613985727

Outcome results

None listed